We serve Chemical Name:5-chloro-2-methoxyphenyl isothiocyanate CAS:63429-99-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:5-chloro-2-methoxyphenyl isothiocyanate
CAS.NO:63429-99-2
Synonyms:MFCD00041073;4-chloro-2-isothiocyanato-1-methoxybenzene
Molecular Formula:C8H6ClNOS
Molecular Weight:199.65700
HS Code:2930909090
Physical and Chemical Properties:
Melting point:56-59°C
Boiling point:164-165°C
Density:1.23 g/cm3
Index of Refraction:1.572
PSA:53.68000
Exact Mass:198.98600
LogP:3.08290
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:2811
Packing Group:III
Contact us for information like MFCD00041073 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-chloro-2-isothiocyanato-1-methoxybenzene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD00041073 Use and application,MFCD00041073 technical grade,usp/ep/jp grade.
Related News: International Chemical Investors Group (ICIG) recently announced it has entered into a purchase agreement under which an affiliate of ICIG will acquire the pharmaceutical intermediates business from Genzyme Corporation. 5-chloro-2-methoxyphenyl isothiocyanate manufacturer The findings were published June 14 in the journal Nature Aging. 5-chloro-2-methoxyphenyl isothiocyanate supplier The foundational patent, which expires in 2034, is owned by MSK and is licensed exclusively to Fate Therapeutics for all human therapeutic uses. 5-chloro-2-methoxyphenyl isothiocyanate vendor International Chemical Investors Group (ICIG) recently announced it has entered into a purchase agreement under which an affiliate of ICIG will acquire the pharmaceutical intermediates business from Genzyme Corporation. 5-chloro-2-methoxyphenyl isothiocyanate factory The increase in environmental protection pressure has also increased the environmental protection expenditure of pharmaceutical manufacturing companies, which forced some small production capacity to withdraw from the market, increased industry concentration, and brought certain opportunities for API manufacturers.
